0001193125-22-207816.txt : 20220801 0001193125-22-207816.hdr.sgml : 20220801 20220801083148 ACCESSION NUMBER: 0001193125-22-207816 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220801 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Other Events FILED AS OF DATE: 20220801 DATE AS OF CHANGE: 20220801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nuvation Bio Inc. CENTRAL INDEX KEY: 0001811063 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 850862255 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39351 FILM NUMBER: 221122913 BUSINESS ADDRESS: STREET 1: 357 TEHAMA STREET, FLOOR 3 CITY: SAN FRANCISCO STATE: CA ZIP: 94103 BUSINESS PHONE: (415) 754-3517 MAIL ADDRESS: STREET 1: 357 TEHAMA STREET, FLOOR 3 CITY: SAN FRANCISCO STATE: CA ZIP: 94103 FORMER COMPANY: FORMER CONFORMED NAME: Panacea Acquisition Corp DATE OF NAME CHANGE: 20200430 8-K 1 d379263d8k.htm 8-K 8-K
false 0001811063 0001811063 2022-08-01 2022-08-01 0001811063 nuvb:ClassACommonStock0.0001ParValuePerShareMember 2022-08-01 2022-08-01 0001811063 nuvb:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtAnExercisePriceOf11.50PerShareMember 2022-08-01 2022-08-01

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 1, 2022

 

 

Nuvation Bio Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39351   85-0862255

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

1500 Broadway, Suite 1401

New York, NY 10036

(Address of principal executive offices)

(332) 208-6102

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Class A Common Stock, $0.0001 par value per share   NUVB   The New York Stock Exchange
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share   NUVB.WS   The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

ITEM 2.02

RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On August 1, 2022, Nuvation Bio Inc. (the “Company”) announced that it expected to report a balance of approximately $703.8 million in cash, cash equivalents and marketable securities as of June 30, 2022.

The information contained in this Item 2.02 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

ITEM 2.05

COSTS ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES

On August 1, 2022, the Company committed to and commenced a restructuring to reduce operating costs and better align its workforce with the needs of its business following the discontinuation of clinical development of NUV-422. The restructuring is expected to be completed in the third quarter of 2022.

Under the restructuring plan, the Company is reducing its workforce by 30 employees (approximately 35%). The Company expects that the workforce reduction will decrease its annual operating costs by approximately $11.8 million.

In connection with the restructuring, the Company estimates that it will incur aggregate restructuring charges of approximately $5.8 million, which will be recorded primarily in the third quarter of 2022, related to severance payments and other employee-related costs, and contract termination costs. The cash payments related to the personnel-related restructuring and contract termination costs will be paid primarily during the third quarter of 2022. The charges that the Company expects to incur in connection with the workforce reduction and contract terminations are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the workforce reduction.

This Item 2.05 contains forward-looking statements, including, but not limited to, statements related to the expected costs associated with termination benefits and the financial impact of the reduction in force. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to cost reduction efforts. In addition, the Company’s workforce reduction costs may be greater than anticipated and the workforce reduction may have an adverse impact on the Company’s development activities. Risks and uncertainties facing the Company are described more fully in its Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on May 9, 2022, under the heading “Risk Factors,” and other documents that the Company has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Item 2.05. The Company disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this Item 2.05.

 

ITEM 8.01

OTHER EVENTS

On August 1, 2022, the Company issued a press release announcing that it was discontinuing clinical development of NUV-422 and implementing the restructuring described above under Item 2.05. The press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

 

Exhibit

Number

   

Description

99.1    Press Release of Nuvation Bio Inc. dated August 1, 2022.
104    Cover Page Interactive Data File (embedded within XBRL document)

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 1, 2022     NUVATION BIO INC.
    By:  

/s/ Jennifer Fox

    Name:   Jennifer Fox
    Title:   Chief Financial Officer

 

3

EX-99.1 2 d379263dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Privileged and confidential

 

LOGO

Nuvation Bio Announces Discontinuation of NUV-422

Clinical Development Program

Company prioritizes NUV-868, its BD2 selective BET inhibitor currently in a Phase 1 dose escalation study in advanced solid tumors, and its novel small molecule Drug-Drug Conjugate (DDC) platform

Company restructuring and cost savings associated with NUV-422 program discontinuation to extend cash runway through 2028

New York, August 1, 2022 – Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that it will prioritize NUV-868 and development of its novel small molecule DDC platform and discontinue clinical development of NUV-422.

The decision to discontinue clinical development of NUV-422 is the result of an internal risk-benefit analysis factoring in feedback received from the U.S. Food and Drug Administration (FDA) in a partial clinical hold letter for the Company’s monotherapy Phase 1/2 study (Protocol NUV-422-02) and clinical hold letters for its combination Phase 1b/2 studies (Protocols NUV-422-03 and NUV-422-04). The FDA verbally placed a partial clinical hold on the Phase 1 dose escalation portion of the Company’s NUV-422-02 study in June 2022. At that time, the Company had proactively paused enrollment of new patients following the emergence of a safety signal, uveitis, which is a form of inflammation of the eye. Furthermore, the FDA requested a mitigation plan to address the adverse event of uveitis. Given that the etiology of uveitis associated with NUV-422 is not understood and that its development appears unpredictable, the Company believes that it would be difficult to craft an effective mitigation plan without significant further research.

Nuvation Bio will intensify its focus and concentrate its resources on the clinical development of NUV-868, its BD2-selective BET inhibitor, and identifying a lead clinical candidate from its novel small molecule DDC platform. Enrollment is ongoing in the Phase 1 monotherapy study of NUV-868, and the Company has planned Phase 1b studies of NUV-868 in combination with olaparib or enzalutamide to enhance the potential value of this program across multiple tumor types.

A reduction in work force of 35% and other cost savings associated with the NUV-422 program discontinuation will enable Nuvation Bio to extend its cash runway through 2028. The Company expects to report a balance of approximately $703.8 million in cash, cash equivalents and marketable securities as of June 30, 2022.

“Nuvation Bio was founded on a commitment to advance a broad pipeline of innovative therapies as quickly and safely as possible for people with cancers that do not currently have adequate treatment options. As part of this commitment, we have always operated as a scientifically rigorous, data-driven company. Following an extensive analysis of the Phase 1 dose escalation study of NUV-422 in solid tumors, we made the determination that uveitis cannot be safely managed. We sincerely thank all patients and investigators who were part of the NUV-422 clinical program for their prodigious efforts. We also thank our employees for their commitment to the Nuvation Bio mission. It was a difficult decision to discontinue the program and we are extremely grateful for each of their contributions,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio.

Privileged and confidential

 

Dr. Hung added: “We believe that our disciplined, data-driven and timely decision to prioritize our other programs over the NUV-422 program based on our most recent clinical data serves to increase our probability of ultimate success in our efforts to bring game-changing drugs to patients who desperately need them. To that end, we are excited to continue enrolling patients in the NUV-868 Phase 1 study and are encouraged by our progress with our novel small molecule DDC platform. With a robust cash balance and a world class drug development team, we are well positioned to progress these priority programs in some of the most difficult-to-treat cancers.”

About Nuvation Bio

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com.

Forward Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Nuvation Bio’s cash balance and cash runway and anticipated patient enrollment in its ongoing Phase 1 and planned Phase 1b studies of NUV-868. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and initiating or conducting clinical trials due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-Q filed with the SEC on May 9, 2022, under the heading “Risk Factors,” and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

Privileged and confidential

 

Nuvation Bio Investor Contact:

ir@nuvationbio.com

Nuvation Bio Media Contact:

Argot Partners

Leo Vartorella

leo@argotpartners.com

EX-101.SCH 3 nuvb-20220801.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 nuvb-20220801_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 nuvb-20220801_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Class A Common Stock 0.0001 Par Value Per Share [Member] Class A Common Stock 0.0001 Par Value Per Share [Member] Redeemable Warrants Each Whole Warrant Exercisable For One Share Of Common Stock At An Exercise Price Of 11.50 Per Share [Member] Redeemable Warrants Each Whole Warrant Exercisable For One Share Of Common Stock At An Exercise Price Of 11.50 Per Share [Member] EX-101.PRE 6 nuvb-20220801_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g379263g0730101726968.jpg GRAPHIC begin 644 g379263g0730101726968.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Aug. 01, 2022
Document And Entity Information [Line Items]  
Amendment Flag false
Entity Central Index Key 0001811063
Document Type 8-K
Document Period End Date Aug. 01, 2022
Entity Registrant Name Nuvation Bio Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39351
Entity Tax Identification Number 85-0862255
Entity Address, Address Line One 1500 Broadway
Entity Address, Address Line Two Suite 1401
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10036
City Area Code (332)
Local Phone Number 208-6102
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Class A Common Stock 0.0001 Par Value Per Share [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Class A Common Stock, $0.0001 par value per share
Trading Symbol NUVB
Security Exchange Name NYSE
Redeemable Warrants Each Whole Warrant Exercisable For One Share Of Common Stock At An Exercise Price Of 11.50 Per Share [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share
Trading Symbol NUVB.WS
Security Exchange Name NYSE
XML 9 d379263d8k_htm.xml IDEA: XBRL DOCUMENT 0001811063 2022-08-01 2022-08-01 0001811063 nuvb:ClassACommonStock0.0001ParValuePerShareMember 2022-08-01 2022-08-01 0001811063 nuvb:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtAnExercisePriceOf11.50PerShareMember 2022-08-01 2022-08-01 false 0001811063 8-K 2022-08-01 Nuvation Bio Inc. DE 001-39351 85-0862255 1500 Broadway Suite 1401 New York NY 10036 (332) 208-6102 false false false false Class A Common Stock, $0.0001 par value per share NUVB NYSE Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share NUVB.WS NYSE false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 3 23 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d379263d8k.htm d379263dex991.htm nuvb-20220801.xsd nuvb-20220801_def.xml nuvb-20220801_lab.xml nuvb-20220801_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d379263d8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "nuvb-20220801_def.xml" ] }, "inline": { "local": [ "d379263d8k.htm" ] }, "labelLink": { "local": [ "nuvb-20220801_lab.xml" ] }, "presentationLink": { "local": [ "nuvb-20220801_pre.xml" ] }, "schema": { "local": [ "nuvb-20220801.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 2, "memberStandard": 0, "nsprefix": "nuvb", "nsuri": "http://nuvationbio.com/20220801", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d379263d8k.htm", "contextRef": "duration_2022-08-01_to_2022-08-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d379263d8k.htm", "contextRef": "duration_2022-08-01_to_2022-08-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "nuvb_ClassACommonStock0.0001ParValuePerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class A Common Stock 0.0001 Par Value Per Share [Member]", "terseLabel": "Class A Common Stock 0.0001 Par Value Per Share [Member]" } } }, "localname": "ClassACommonStock0.0001ParValuePerShareMember", "nsuri": "http://nuvationbio.com/20220801", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "nuvb_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://nuvationbio.com/20220801", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "nuvb_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://nuvationbio.com/20220801", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "nuvb_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtAnExercisePriceOf11.50PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeemable Warrants Each Whole Warrant Exercisable For One Share Of Common Stock At An Exercise Price Of 11.50 Per Share [Member]", "terseLabel": "Redeemable Warrants Each Whole Warrant Exercisable For One Share Of Common Stock At An Exercise Price Of 11.50 Per Share [Member]" } } }, "localname": "RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtAnExercisePriceOf11.50PerShareMember", "nsuri": "http://nuvationbio.com/20220801", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nuvationbio.com//20220801/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-22-207816-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-207816-xbrl.zip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end